A type of circulating stromal cell, CAMLs arise as part of an innate immune response, which could make them useful for predicting the presence of cancer. That would be particularly useful as the cells can be isolated from peripheral blood, making a test non-invasive.
Black women are more likely to die of uterine cancer than white women, even though the incidence rate is the same between the two groups.
For many rural patients, receiving timely, quality cancer care remains difficult. Challenges include transportation hurdles, financial constraints, a lack of providers, and minimal access to clinical trials. As a result, while cancer incidence rates are lower in rural areas, cancer mortality rates are higher.
In 2015, the American Society of Clinical Oncologists (ASCO) named the transformation of chronic lymphocytic leukemia (CLL) the Cancer Advance of the Year.
Rates of colorectal cancer have been rising in younger patients since the mid-1980s, even as rates have fallen in individuals over age 50, according to the American Cancer Society.
Real world results often differ markedly from those seen in clinical trials. In the very real world setting of the VA, does immunotherapy really provide greater benefit than chemotherapy for patients with lung cancer?
Increased personalization of cancer therapy has transformed oncology over the past decade as a growing number of targeted therapies have entered the market.
Over the last few years, two combinations have dueled for primacy in treatment of lymphomas: DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
Among veterans, renal cell carcinoma (RCC) accounts for 3% of all diagnosed malignancies or approximately 2,250 new diagnoses each year.
The National Comprehensive Cancer Network (NCCN) Guidelines continue to recommend conducting a skeletal survey or whole-body radiography as the first step in identifying osteolytic bone lesions and distinguishing between smoldering multiple myeloma (SMM) and multiple myeloma (MM).
Every physician knows each patient is different. Prognostic models, however, tend to assume everyone’s the same. That can skew decisions in cancer care.
Across the VA system, immune checkpoint inhibitors (ICIs) are being prescribed for a growing number of cancer types including renal cell carcinoma, lung cancer, head and neck cancers, and melanoma.